Literature DB >> 1413465

Hemimaxillectomy for the treatment of oral tumors in 69 dogs.

J Wallace1, D T Matthiesen, A K Patnaik.   

Abstract

Hemimaxillectomy was performed in 69 dogs for the treatment of benign or malignant maxillary tumors. Eighteen dogs with ameloblastomas had a median disease-free interval of 21.5 months (range, 1 to 76 months), with a 72% 1-year survival time. There was recurrence in three dogs, with metastasis after malignant transformation in one of them. Based on calculated survival curves, seven dogs with squamous cell carcinoma had a median survival time of 19.2 months (range, 2 to 24 months), with a 57% 1-year survival time. There was local recurrence in two dogs. Twenty-three dogs with melanoma had a median survival time of 9.1 months (range, 1 to 46 months), and a 27% 1-year survival time. Twelve dogs died or were euthanatized because of recurrence or metastases. Fifteen dogs with fibrosarcoma had a median survival time of 12.2 months. Eight dogs died or were euthanatized because of recurrence or metastases. Six dogs with osteosarcoma had a median survival time of 4.6 months (range, 1 to 12.5 months), with a 17% 1-year survival time. Five dogs died or were euthanatized for recurrence or metastases. Tumor size or location and type of partial maxillectomy performed did not affect survival.

Entities:  

Mesh:

Year:  1992        PMID: 1413465     DOI: 10.1111/j.1532-950x.1992.tb01707.x

Source DB:  PubMed          Journal:  Vet Surg        ISSN: 0161-3499            Impact factor:   1.495


  14 in total

Review 1.  Radiation therapy of canine nontonsillar squamous cell carcinoma.

Authors:  Candace K Grier; Monique N Mayer
Journal:  Can Vet J       Date:  2007-11       Impact factor: 1.008

2.  Nasal-skin-fold transposition flap for upper lip reconstruction in a French bulldog.

Authors:  Manuel Benlloch-Gonzalez; Stéphanie Lafarge; Bernard Bouvy; Cyrill Poncet
Journal:  Can Vet J       Date:  2013-10       Impact factor: 1.008

3.  6-Bromoindirubin-3'oxime (BIO) decreases proliferation and migration of canine melanoma cell lines.

Authors:  Esther Chon; Brandi Flanagan; Lucas Campos de Sá Rodrigues; Caroline Piskun; Timothy J Stein
Journal:  Vet J       Date:  2014-07-31       Impact factor: 2.688

4.  Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and anti-CSPG4 vaccination: A retrospective study on 68 cases (2010-2020).

Authors:  Mariateresa Camerino; Davide Giacobino; Luca Manassero; Selina Iussich; Federica Riccardo; Federica Cavallo; Lidia Tarone; Matteo Olimpo; Elena Lardone; Marina Martano; Sara Del Magno; Paolo Buracco; Emanuela Morello
Journal:  Vet Comp Oncol       Date:  2021-09-06       Impact factor: 2.385

5.  A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma.

Authors:  Elisabetta Treggiari; Jessica Pauline Grant; Susan Margaret North
Journal:  J Vet Med Sci       Date:  2016-01-15       Impact factor: 1.267

6.  PDPN Is Expressed in Various Types of Canine Tumors and Its Silencing Induces Apoptosis and Cell Cycle Arrest in Canine Malignant Melanoma.

Authors:  Masahiro Shinada; Daiki Kato; Satoshi Kamoto; Sho Yoshimoto; Masaya Tsuboi; Ryohei Yoshitake; Shotaro Eto; Namiko Ikeda; Kohei Saeki; Yuko Hashimoto; Yosuke Takahashi; James Chambers; Kazuyuki Uchida; Mika K Kaneko; Naoki Fujita; Ryohei Nishimura; Yukinari Kato; Takayuki Nakagawa
Journal:  Cells       Date:  2020-05-05       Impact factor: 6.600

7.  A possible role of coarse fractionated radiotherapy in the management of gingival squamous cell carcinoma in dogs: A retrospective study of 21 cases from two referral centers in the UK.

Authors:  Andrea Mosca; Danielle Gibson; Sarah L Mason; Jane Dobson; Antonio Giuliano
Journal:  J Vet Med Sci       Date:  2021-01-25       Impact factor: 1.267

8.  Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.

Authors:  L A Piras; F Riccardo; S Iussich; L Maniscalco; F Gattino; M Martano; E Morello; S Lorda Mayayo; V Rolih; F Garavaglia; R De Maria; E Lardone; F Collivignarelli; D Mignacca; D Giacobino; S Ferrone; F Cavallo; P Buracco
Journal:  Vet Comp Oncol       Date:  2016-05-04       Impact factor: 2.613

9.  Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.

Authors:  Milan Milovancev; Stuart C Helfand; Kevin Marley; Cheri P Goodall; Christiane V Löhr; Shay Bracha
Journal:  BMC Vet Res       Date:  2016-06-04       Impact factor: 2.741

10.  Clinical features and treatment outcomes of 41 dogs with sublingual ectopic thyroid neoplasia.

Authors:  M R Broome; M E Peterson; J R Walker
Journal:  J Vet Intern Med       Date:  2014-07-23       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.